Management team

Anders Karlsson

CEO since 2019

Anders Karlsson has extensive international experience in Life Science, both from pharmaceutical and medical technology companies. Anders was CEO and Country President of Novartis in Norway 2003 – 2006 and thereafter CEO of the medical technology companies AbSorber AB, Olerup International AB och Olerup SSP AB 2007-2011.

In May 2011, he was appointed CEO of Nasdaq-listed Allenex AB, that develops, manufactures and sells transplant diagnostics products globally. In 2016, Allenex was acquired by Nasdaq, USA- listed CareDx Inc. Since then, Karlsson has been President and Managing Director of CareDx International AB and responsible for global operations outside the US and part of the company’s global management team.

In addition to leading operational roles, Anders has also gained a broad national and international experience from board assignments within Life science companies.

Anders Karlsson holds a MBA from Henley Business School, University of Reading, UK and management education from London Business School and Harvard.

Holdings: 35, 000 shares

Warrants: 120, 000

Ingvar Karlsson

CFO since 2016

Ingvar Karlsson has a broad experience from qualified positions in several large companies. Most recently Ingvar was CFO of Lekolar Group, before that, he was CFO of Doro AB, which is listed on the NASDAQ OMX Nordic Exchange Small Cap List in Stockholm. Ingvar has also held positions as controller at the Gambro Group and as CFO and controller of Perstorp AB. Ingvar Karlsson holds a M.Sc. in Economics and Business from Lund University.

Holdings: 15, 333 shares

Warrants: 30, 000

Åsa Schiött

CSO since 2020

Åsa Schiött has many years of experience within drug development by working in the biotech and pharmaceutical industry for more than 20 years. Åsa has worked in small and medium sized biotech companies within the immunological areas of vaccine, cancer and transplantation.  She has led several development projects, from non-clinical safety studies to the completion of clinical phase II trials as a senior project manager. She has been involved in EU marketing authorisation applications and US IND applications and has knowledge of document requirements, data standards e.g. eCTD and CDISC, etc.

Åsa holds a PhD in Tumor Immunology and a Post Doc in Immunology from the Tumor Immunology and Immunothechnology departments of Lund University, respectively. Åsa has substantial research experience within immunology, including dendritic cells, but also transplantation.

Holdings: –

Warrants: 30,000

Dennis Henriksen

CTO since 2015

Dennis Henriksen joined Idogen in 2014. He has over 20 years managerial industry experience in small to medium size biotechnology companies, including several years in the United States as Vice President of BioNebraska Inc. where he also served as a member in the corporate management group and was responsible for R&D. Dennis has long experience of developing and implementing cGMP in small to medium size biotech companies and has been involved in research and development programs within many different fields, including arthritic diseases, inflammatory and autoimmune diseases and several forms of cancer. Dennis Henriksen holds a M.Sc. in chemical engineering from the Technical University of Copenhagen and a Ph.D. in bioorganic chemistry from the University of Copenhagen.

Holdings: 12, 343 shares

Neil Thomas

CBO since 2015

Neil Thomas joined Idogen in October 2014. He has worked in the biotechnology sector for over 20 years, with experience in company formation, fund-raising, IP portfolio management, business development, licensing and technology exploitation. Previously, he was director of Business Development & IP at Genetrix, Madrid and before that Director of IP & Technology at Roche spin-out BioXell in Milan. His experience also includes working in London-based European Patent Attorney firms, as well as assignments as a member of the board of Genetrix Life Sciences AB (Sweden), Biobide SL and Sensia SL. Neil Thomas holds a B.Sc. in Biological Sciences from the University of Birmingham and a Ph.D. in Biochemistry and Molecular Biology from the University of Durham. He was also Adjunct Professor of IP in the Life Sciences Industry at IE Business School in Madrid from 2010 to 2015.

Holdings: 3, 143 shares

Christina Brattström

CMO since 2020

Christina Brattström is a medical doctor and holds a PhD from Karolinska Institutet where she also has been active as Associate Professor and been  responsible for clinical drug tests in transplant medicine. Since 2000, she has had leading positions in the pharmaceutical industry and will contribute a broad experience from both clinical development and the regulatory sphere. Christina Brattström has previously worked at Wyeth as Medical Advisor and Head of CRA Group with responsibility for clinical trials. Furthermore, Christina has worked at Abbot as Medical Director and head of one of the company’s Regulatory Affairs groups. She most recently comes from the pharmaceutical company Bayer AB where she has been Scandinavian Medical Director and had the medical responsibility for hemophilia medicines.


Vicki Venizelos

CRO since 2020

Vicki Venizelos has held various CMC and regulatory roles in the biotechnology and pharmaceutical industry for more than 20 years. She began applying her experience in the field of ATMP development 14 years ago. Companies Vicki has worked for range from small to medium size biotechnology companies through to large multinationals, where she has helped enable first-in-human studies through to further clinical development, EU marketing authorisation applications and US biologics license applications. Vicki holds a B.Sc. in Chemistry and Microbiology from the University of South Australia, and business education from the Rotterdam University of Applied Sciences. Apart from her role at Idogen, Vicki is the owner of a CMC and regulatory consultancy company based in Leiden, the Netherlands.


Warrants: 10,000

Terese Hylander

Project & Communications Mgr since 2019

Terese Hylander has broad knowledge of cell-based immunological research and hitherto worked as a senior scientist with focus on human dendritic cells and development of the company’s technology. She has for several years also carried the responsibility for important areas of internal communication, facility management as well as a key role in coordinating early research work and the transfer into further development. Terese Hylander holds a M. Sc in Biomedicine from Kalmar University and a Ph.D. in immunology from Karolinska Institute.

Holdings: 10, 034 shares

Warrants: 30, 000